摘要：

The article discusses various reports published within the issue, including one by Rosamaria Lappano and Marcello Maggiolini on the role of G protein-coupled receptors (GPCRs) in tumour progression, one by Joseph A. DiMasi and Laura B. Faden on the development and patent filing histories of new drug classes in the U.S. over the past 50 years, and one by Elisabeth Perzborn and colleagues on the discovery and development of the drug, rivaroxaban.

展开